Prostate cancer

  1. Cypides: Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer
    The purpose of the study is to assess the safety and tolerability of the trial drug ODM-208 in patients diagnosed with prostate cancer.
    Primary researcher: Tapio Utriainen

  2. A randomized, double-blind, placebo-controlled phase III study of ODM-201 versus placebo inaddition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
    The purpose of this study is to compare standard androgen deprivation therapy and the drug ODM-201 in combination with docetaxel to a placebo in patients with metastatic hormone-sensitive prostate cancer.
    Primary researcher: Tapio Utriainen
 

 Contact Information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680